THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.9] ID: TIP-MED-000193

Zinc (Zinc Sulphate Monohydrate / Zinc Acetate / Zinc Gluconate)

Active Ingredient / Scientific Identity: Zinc • Class: Essential Trace Element Cofactor (>300 Metalloenzymes: DNA/RNA Polymerase, Alkaline Phosphatase, Carbonic Anhydrase, Superoxide Dismutase, Epithelial & Immune Repair)

⚖️ Compare Profile
Generic / Entity NameZinc (Zinc Sulphate Monohydrate / Zinc Acetate / Zinc Gluconate) ([10.9])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassEssential Trace Element Cofactor (>300 Metalloenzymes: DNA/RNA Polymerase, Alkaline Phosph
Available Dosage FormsOral Dispersible Tablets & Syrups: 20 mg Elemental Zinc (equivalent to ~55 mg Zinc Sulphate Monohydrate); Adul
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: Excreted primarily via faeces (~90%); safe in short courses in CKD, though avoid chronic high doses. Hepatic: Zinc sup
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Zinc (Zinc Sulphate Monohydrate / Zinc Acetate / Zinc Gluconate) (TIP-MED-000193, Reference Code [10.9]) is classified under Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Essential Trace Element Cofactor (>300 Metalloenzymes: DNA/RNA Polymerase, Alkaline Phosphatase, Carbonic Anhydrase, Superoxide Dismutase, Epithelial & Immune Repair). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.9], p. 131): Zinfate / Zinconia (Zuventus—20 mg elemental Zn), Zincovit (Apex—Multivitamin + Zinc), Z&D (Alkem), Ascazin (50 mg elemental Zn) — Strengths & Dosage Forms: Oral Dispersible Tablets & Syrups: 20 mg Elemental Zinc (equivalent to ~55 mg Zinc Sulphate Monohydrate); Adult Therapeutic Tablets: 50 mg Elemental Zinc (equivalent to 140 mg Zinc Sulphate Monohydrate or 220 mg Zinc Sulphate Heptahydrate)
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.9], p. 131): Zinfate / Zinconia (Zuventus—20 mg elemental Zn), Zincovit (Apex—Multivitamin + Zinc), Z&D (Alkem), Ascazin (50 mg elemental Zn) — Strengths & Dosage Forms: Oral Dispersible Tablets & Syrups: 20 mg Elemental Zinc (equivalent to ~55 mg Zinc Sulphate Monohydrate); Adult Therapeutic Tablets: 50 mg Elemental Zinc (equivalent to 140 mg Zinc Sulphate Monohydrate or 220 mg Zinc Sulphate Heptahydrate)
Dosage Forms & Available Strengths:
Oral Dispersible Tablets & Syrups: 20 mg Elemental Zinc (equivalent to ~55 mg Zinc Sulphate Monohydrate); Adult Therapeutic Tablets: 50 mg Elemental Zinc (equivalent to 140 mg Zinc Sulphate Monohydrate or 220 mg Zinc Sulphate Heptahydrate)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Essential Trace Element Cofactor (>300 Metalloenzymes: DNA/RNA Polymerase, Alkaline Phosphatase, Carbonic Anhydrase, Superoxide Dismutase, Epithelial & Immune Repair) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Essential Trace Element Cofactor (>300 Metalloenzymes: DNA/RNA Polymerase, Alkaline Phosphatase, Carbonic Anhydrase, Superoxide Dismutase, Epithelial & Immune Repair) for WHO / ICMR Mandatory Adjunct to ORS in Acute Infectious Diarrhoea in children (20 mg OD for 14 days—reduces stool volume and prevents recurrence for 2–3 months!) and adults; promotion of wound, pressure ulcer, diabetic foot ulcer, and burn healing; acrodermatitis enteropathica; immune convalescence; dysgeusia/hypogeusia (impaired taste); Wilson's Disease (Zinc Acetate 50 mg TDS induces intestinal metallothionein to block dietary copper absorption!)..

4. Therapeutic Indications & Evidence-Supported Uses

  • WHO / ICMR Mandatory Adjunct to ORS in Acute Infectious Diarrhoea in children (20 mg OD for 14 days—reduces stool volume and prevents recurrence for 2–3 months!) and adults
  • promotion of wound, pressure ulcer, diabetic foot ulcer, and burn healing
  • acrodermatitis enteropathica
  • immune convalescence
  • dysgeusia/hypogeusia (impaired taste)
  • Wilson's Disease (Zinc Acetate 50 mg TDS induces intestinal metallothionein to block dietary copper absorption!)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Nutritional / Immune / Wound Supplementation: 20 mg to 50 mg Elemental Zinc once daily after food for 2–4 weeks. Acute Diarrhoea: 20 mg elemental zinc once daily for 10–14 days. (Wilson's Disease maintenance: 50 mg elemental zinc three times daily on an empty stomach). Follow physician prescription.

Administration & Meal Timing: Take WITH or immediately AFTER a meal (except in Wilson's disease)—taking zinc on an empty stomach causes intense gastric irritation, metallic nausea, and vomiting! | Once daily after lunch or dinner.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Excreted primarily via faeces (~90%); safe in short courses in CKD, though avoid chronic high doses. Hepatic: Zinc supplementation (20–50 mg/day) is often beneficial in hepatic cirrhosis (where urinary zinc wasting impairs urea cycle ornithine transcarbamylase ammonia detoxification).
Elimination & Renal Adjustment:
Renal: Excreted primarily via faeces (~90%); safe in short courses in CKD, though avoid chronic high doses. Hepatic: Zinc supplementation (20–50 mg/day) is often beneficial in hepatic cirrhosis (where urinary zinc wasting impairs urea cycle ornithine transcarbamylase ammonia detoxification).
Hepatic Impairment Considerations:
Renal: Excreted primarily via faeces (~90%); safe in short courses in CKD, though avoid chronic high doses. Hepatic: Zinc supplementation (20–50 mg/day) is often beneficial in hepatic cirrhosis (where urinary zinc wasting impairs urea cycle ornithine transcarbamylase ammonia detoxification).

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Chronic Zinc Overuse Causes Severe Copper-Deficiency Anaemia & Myeloneuropathy! Taking high-dose Zinc (≥50 mg elemental Zn/day) continuously for months induces intestinal metallothionein, which traps dietary Copper inside enterocytes and excretes it in faeces—leading to hypocupraemic microcytic/sideroblastic anaemia, neutropenia, and irreversible spinal cord neuropathy!

Key Clinical Precautions: Renal: Excreted primarily via faeces (~90%); safe in short courses in CKD, though avoid chronic high doses. Hepatic: Zinc supplementation (20–50 mg/day) is often beneficial in hepatic cirrhosis (where urinary zinc wasting impairs urea cycle ornithine transcarbamylase ammonia detoxification).

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Nausea, epigastric burning, metallic/astringent taste in mouth (especially if taken on an empty stomach or as dispersible zinc sulphate), abdominal cramping.
  • Zinc-Induced Copper Deficiency (sideroblastic anaemia, severe leukopenia/neutropenia, sensory ataxia/myeloneuropathy) with chronic megadose intake; reduction in HDL cholesterol with prolonged high doses.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Chelation Blockade (Space by ≥2–4 Hours!): Zinc chelates and blocks the absorption of Fluoroquinolones (ciprofloxacin, levofloxacin, ofloxacin), Tetracyclines (doxycycline), Penicillamine, Trientine, and Integrase Inhibitors (dolutegravir)! Furthermore, high-dose Oral Iron and Calcium compete with Zinc for intestinal absorption if taken simultaneously in large doses

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Always take Zinc tablets after lunch or dinner to avoid stomach nausea. Space by at least 2–3 hours from Ciprofloxacin, Levofloxacin, or Doxycycline antibiotics. Post-COVID/viral illness patients should not continue 50 mg Zinc tablets indefinitely beyond 2–4 weeks, as excess zinc blocks copper and weakens blood counts.
  • Meal & Clock Timing Instruction: Take WITH or immediately AFTER a meal (except in Wilson's disease)—taking zinc on an empty stomach causes intense gastric irritation, metallic nausea, and vomiting! (Once daily after lunch or dinner.)
  • Missed Dose Protocol: Take after the next meal; never double.
  • Geriatric Dispensing Pearl: Beneficial for 2–4 weeks in elderly patients with diabetic foot ulcers, venous leg ulcers, or acute gastroenteritis, but audit chronic prescriptions to prevent prolonged duplicate zinc intake (e.g., taking both Zincovit and Ascazin).

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Dispersible Tablets & Syrups: 20 mg Elemental Zinc (equivalent to ~55 mg Zinc Sulphate Monohydrate); Adult Therapeutic Tablets: 50 mg Elemental Zinc (equivalent to 140 mg Zinc Sulphate Monohydrate or 220 mg Zinc Sulphate Heptahydrate)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.9] (p. 131)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.